SHANGHAI, September 3, 2025 — Leads & Copy — Fangzhou Inc. (06086.HK), a leader in AI-driven Internet healthcare solutions, announced its technology team will collaborate on a National Natural Science Foundation of China (NSFC) project led by Sun Yat-sen University professor Liang Jianping. This marks the company’s second NSFC-backed research partnership.
The study will examine the influence of human-AI collaboration models on consumer adoption. Fangzhou, the project’s sole corporate partner, will focus on “AI + chronic disease management” and collaborate with the research team to examine how human–AI collaboration affects consumer adoption of healthcare products and services. The company will also provide support on real-world data collection and model optimization. The project aims to enrich academic understanding in AI and cognitive science, while accelerating the application of AI in healthcare.
Fangzhou previously contributed to an NSFC project on AI supervision and online consumer behavior in 2024, led by professor Wang Haizhong of Sun Yat-sen University. These projects underscore Fangzhou’s role in advancing industry-academia collaboration and highlight its commitment to enhancing technical expertise and strengthening AI innovation in healthcare.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, “Our continued participation in NSFC projects shows that Fangzhou is not only driving commercial success through AI-driven healthcare, but also contributing to China’s broader innovation agenda.”
China has elevated artificial intelligence to a strategic national priority. Fangzhou has invested heavily in research talent and AI innovation, including the “H2H Smart Healthcare Ecosystem.”
Fangzhou will continue to strengthen participation in national research initiatives and build integrated industry–academia–research innovation platforms, with the goal of translating academic achievements into public healthcare services and contributing to the “Healthy China 2030” goals.
About Fangzhou Inc.: Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and precision medicine solutions.
Media Contact:
Xingwei Zhao
Associate Director of Public Relations
Email: pr@jianke.com
Source: Fangzhou Inc.
